Nidufexor
Nidufexor is an agonist of Farnesoid X receptor (FXR). Administration of Nidufexor (10 and 30 mg/kg for 3 weeks) modulates FXR-dependent genes in vivo leading to the reduction of steatosis, inflammation, and fibrosis in a murine NASH model. It is in clinical trials in patients with nonalcoholic steatohepatitis (NASH) and diabetic nephropathy.
Product Specifications
Shipping Conditions
Gel Pack
Storage Conditions
-20ºC
Shelf Life
36 months
More Discoveries
Explore Other Products
Browse additional items from our catalog
